Why this was commissioned

Anthony Booth is a marketing director with twenty-five years in lead generation, customer acquisition, conversion economics, and the analytics that sit underneath them. He has no formal medical training. He has, like most informed laypeople of his generation, opinions about cholesterol and statins that have been shaped by a confused public conversation, two decades of pharmaceutical advertising, a counter-movement of low-carb and statin-sceptic voices on social media, occasional newspaper coverage of trial controversies, and an underlying suspicion — earned across his career working alongside data systems and incentive structures — that what gets sold and what is true are often only loosely correlated.

He has a friend who works at Roche. The friend is industry-adjacent, scientifically literate, and is going to bring real evidence to the conversation. Anthony does not want to walk into that conversation with the casual cocktail-party position of someone who has read a few articles. He wants to walk in with the kind of grasp of the topic that a post-graduate student would have after six weeks of intensive reading — enough to know what is settled and what is genuinely contested, enough to recognise when a confident claim is leaning on stronger or weaker evidence, enough to know the names of the people on each side of every dispute and what their best arguments are, and enough to land a defensible position of his own rather than ricocheting between camps.

That is an unusual thing to commission, and worth pausing on. Most people, faced with a domain they don't understand, do one of three things. They defer entirely to authority — in this case, "what does my GP say" — which is reasonable but evades the conversation Anthony wants to have. They go contrarian — "I've read this is a scam" — which feels powerful but loses the conversation on the evidence within the first ten minutes against anyone who has actually read the trials. Or they triangulate inconsistently — "well, some studies show... but others show..." — which leaves them unable to commit to any position and therefore unable to be persuaded out of one or to defend it.

Anthony asked for a fourth option: a steelmanned, calibrated, post-graduate-level synthesis that would let him do something rare in public conversation about contested science. He wanted to be able to grant the strongest version of the other side's argument before stating his own; to know where the evidence is genuinely strong and where it is genuinely thin; to have specific trials, dates, effect sizes, and named participants in his head; to have a position that could survive being argued against by someone better informed than him, because the position would already have absorbed the strongest counter-arguments before he arrived at it.

This is also why he asked for the meta-layer first — the prompt, the agent topology, the methodological arc — before any of the substantive writing began. He wanted to see the scaffolding. As someone who has built marketing systems for two and a half decades, he knows that the quality of a complex output is determined more by the architecture that produced it than by anything that happens at the surface. A 100-page document that looks polished can be cargo-cult science; a rougher document built on the right epistemic spine is more trustworthy. He wanted to inspect the spine before commissioning the body.

The deeper reason, though — the one worth saying out loud — is that the cholesterol-and-statins question is a particularly interesting test case for whether informed lay reasoning about complex medicine is actually possible. The topic has all the features that usually defeat lay reasoning: the underlying biology is genuinely complicated; the empirical literature is enormous and methodologically uneven; the financial stakes are large enough to have demonstrably corrupted some specific trials and analyses; the consensus camp and the heterodox camp have both, at different points, been overconfident in their respective directions; the popular discourse oscillates between "cheap miracle drug" framing and "Big Pharma scam" framing without ever doing the patient work of figuring out where the evidence actually lands. If a marketing director can come out of six weeks of synthesis with a calibrated position, then the project of informed lay reasoning is at least possible. If not, then perhaps medicine genuinely is too specialised for non-specialists to engage with substantively, and the only honest stances available to laypeople are defer-to-authority or admit-uncertainty. Anthony, characteristically, is treating his Roche conversation as the practical test of which is true.

There is one more reason worth naming. Anthony's professional life has been about understanding the difference between what is genuinely persuasive and what merely feels persuasive. He has spent decades watching marketing claims that sound authoritative collapse under data and marketing claims that sound modest survive it. He brings this calibrated suspicion to any domain where confident assertions and underlying evidence don't obviously line up. Medicine is one of those domains, and the cholesterol question — sitting at the intersection of cardiology, pharmacology, statistics, public-health policy, and pharmaceutical commerce — is one of its sharpest cases. Treating it well requires the kind of evidence-weighted, source-aware, both-sides-steelmanned analysis that good marketers spend their careers learning to recognise.

The document that follows is the answer to a question Anthony asked clearly: can a non-clinician, with the right scaffolding, arrive at a defensible position in a domain that usually defeats non-clinicians?

The document's existence is the answer's first half. The conversation with the friend at Roche will be the second.